MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 5 Hold Rating(s), 7 Buy Rating(s)
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $71.44 (67.04% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016Goldman Sachs Group Inc.Reiterated RatingHold$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Janney Montgomery ScottReiterated RatingNeutral$52.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$50.00 -> $62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Canaccord GenuityUpgradeHold -> Buy$50.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Leerink SwannReiterated RatingMarket Perform$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016Credit Suisse Group AGBoost Price TargetOutperform$65.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016SunTrust Banks Inc.Boost Price TargetBuy$57.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015DesjardinsUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Citigroup Inc.Initiated CoverageNeutral$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015MLV & Co.Initiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q415($0.50)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.92)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015Q414($0.58)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.53)$0.10$8.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.41)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.38)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.28)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.48)($0.52)
Q2 20163($1.33)($1.15)($1.23)
Q3 20163($1.42)($1.19)($1.30)
Q4 20163($1.49)($0.91)($1.23)
(Data provided by Zacks Investment Research)
Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline
07/01/16 07:36 PMTracking Stock Volatility for: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
06/30/16 10:15 AMRecent Study: Gallbladder Cancer - Pipeline Review, H1 2016
06/29/16 10:36 AMRecently Issued Stock Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Fiscal Standard
06/28/16 07:34 AMTop Stock Pick for Quarter: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
06/28/16 07:34 AMStrong Sell Calls Recommendations For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) At 0 - Investor Newswire
06/27/16 02:43 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Earnings Glance and Target Price Review - Engelwood Daily
06/25/16 02:22 PMStock Tracing Lower on the Week Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
06/25/16 09:27 AMAnalyst Review Alert: Agios Pharmaceuticals Inc (NASDAQ:AGIO)
06/24/16 07:35 PMNew Broker Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - FTSE News
06/23/16 03:49 PMAGIOS PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/22/16 03:10 PMAGIOS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/22/16 07:08 AMCommit To Purchase Agios Pharmaceuticals At $35, Earn 15.6% Annualized Using Options - Nasdaq
06/21/16 07:08 AMStrong Buy Calls Count For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) At 4 - Investor Newswire
06/20/16 02:21 PMCanaccord Genuity Upgrades Agios Pharmaceuticals Inc to Buy with Price Target $90.00 - TheFounders Daily
06/17/16 10:16 AMCurrent Update on Price Fluctuations: TG Therapeutics, Inc. (NASDAQ:TGTX) , Agios Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
06/16/16 06:01 AMAgios Pharmaceuticals Inc. (AGIO) Drops 6.2% on June 14 - Equities.com
06/15/16 07:25 PMWhat should one expect from? - Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Sanchez Energy Corporation (NYSE:SN) - Beacon Chronicle
06/15/16 02:23 PMAgios Drives Towards Approval - Seeking Alpha
06/14/16 02:22 PMTake a look at Analyst Tips: Sophiris Bio, Inc. (NASDAQ:SPHS) , Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Street Updates
06/14/16 07:10 AMTop Analyst Upgrades and Downgrades: AMD, Agios Pharma, Baidu, Diamond Offshore, LyondellBasell, Occidental ... - 24/7 Wall St.
06/13/16 02:22 PMHC Stocks Reports Analysis: Organovo Holdings Inc (NYSEMKT:ONVO), Agios Pharmaceuticals Inc (NASDAQ:AGIO) - share market updates (press release)
06/13/16 02:22 PMAgios Pharmaceuticals Inc (AGIO), Direxion Shares Exchange Traded Fund Trust (JNUG), B CommunicationsLtd ... - TCC
06/13/16 02:22 PMAgios Pharmaceuticals Inc (NASDAQ:AGIO)'s AG-348 Excites In Phase 2 Study - Market Exclusive
06/13/16 01:35 PMStreet Talk: MDT, AGIO, NVD & more -
06/13/16 10:33 AMAgios Pharmaceuticals: So Much the Good News -
06/13/16 10:28 AMGoldman Sachs: 3 Questions For Agios Pharmaceuticals
06/13/16 10:28 AMTop Analyst Upgrades and Downgrades: AMD, Agios Pharma, Baidu, Diamond Offshore, LyondellBasell, Occidental Petroleum and More
06/13/16 10:28 AMAnalyst Upgrades: Agios Pharmaceuticals Inc, Alibaba Group Holding Ltd, and Royal Gold, Inc (USA)
06/13/16 10:28 AMAgios Pharmaceuticals Inc (AGIO)’s AG-348 Excites In Phase 2 Study
06/13/16 10:05 AMAgios Pharmaceuticals briefly spikes after positive study results -
06/12/16 07:39 PMAgios Drug Boosts Hemoglobin in Small Rare Blood Disease Trial
06/11/16 10:32 AMAgios Pharmaceuticals Inc.: AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and ... - The Wall Street Transcript
06/11/16 10:32 AMAgios Pharmaceuticals Inc. (AGIO) Drops 14.93% on June 09 - Equities.com
06/11/16 10:15 AMAgios drug boosts hemoglobin in anemia patients in mid-stage trial -
06/11/16 08:30 AMAgios Pharmaceuticals Inc Conference Call to Discuss Data from PKR Activators AG-348 and AG-519 scheduled for 9:30 am ET today -
06/11/16 07:19 AMAG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency - [at noodls] - - 9 of 18 Total Patients and 9 of 13 Patients with at Least One Missense Mutation Showed Maximal Hemoglobin Increases Between 2.3 to 4.9 g/dL - - AG-348 Well Tolerated with Up to Six Months of Daily Dosing ...
06/10/16 08:04 PMAgios Pharma (AGIO) Announces Data from AG-519 Phase 1 SAD, MAD; Dose-Dependent Increase in PKR Activity ... - StreetInsider.com
06/10/16 10:45 AMAgios Pharmaceuticals (AGIO) Stock: Weak On High Volume Today - TheStreet.com
06/10/16 10:45 AMAnalyst Opinion on these Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), GameStop Corp. (NYSE:GME) - Beacon Chronicle
06/10/16 10:45 AMAnalyst's Valuable Buzzers: Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) , Agios Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
06/10/16 09:04 AMThis Is Why Agios Pharmaceuticals' Stock Rose 14.3% in May -
06/09/16 08:14 PMWhy Agios Pharmaceuticals Inc. Presented Lower Today - Motley Fool
06/09/16 02:58 PMWhy Agios Pharmaceuticals Inc. Presented Lower Today -
06/09/16 02:20 PMAnalyst Update: Agios Pharmaceuticals Inc, Chesapeake Energy Corporation, and Fitbit Inc - Schaeffers Research (blog)
06/09/16 02:20 PMEarnings Expectation Watch List: DSW Inc. (NYSE:DSW), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Beacon Chronicle
06/09/16 11:12 AMTwo Stocks within Traders Observation: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) , Adeptus Health Inc. (NYSE:ADPT) - Street Updates
06/09/16 11:12 AMCompany Update (NASDAQ:AGIO): Agios Pharmaceuticals Inc Reports Initial Data from Phase 1 Study of AG-519 in ... - Smarter Analyst
06/09/16 08:39 AMAgios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers - [at noodls] - - Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing - - Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation - - Company ...
06/09/16 08:22 AM9:22 am Agios Pharma announces initial data from the phase I clinical trial of AG-519 at the European Hematology Association providing early 'proof-of-mechanism' -
06/08/16 10:49 AMAgios Pharmaceuticals Inc. (AGIO) Jumps 5.07% on June 06 - Equities.com
About Agios Pharmaceuticals

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGIO
  • CUSIP:
Key Metrics:
  • Previous Close: $42.77
  • 50 Day Moving Average: $50.49
  • 200 Day Moving Average: $47.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.62B
  • Current Quarter EPS Consensus Estimate: $-3.31 EPS
Additional Links:
Agios Pharmaceuticals (NASDAQ:AGIO) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha